Yes we Can-Fite PDAC; phase IIa results add momentum
· randy osborne
AI Briefing
- • Can-Fite Biopharma shares surge 58% after positive phase IIa results for pancreatic ductal adenocarcinoma treatment.
- • The treatment has shown encouraging results, boosting Can-Fite's shares to $4.70 on July 1.
- • Can-Fite's stock price rose $1.73 following the announcement.
Context
Can-Fite Biopharma Ltd, a company based in Ramat Gan, Israel, has released phase IIa results for pancreatic ductal adenocarcinoma treatment. The company's shares, listed as CANF on the NYSE, increased by 58% after the results were announced.
The increase in share price, which rose by $1.73 to $4.70 on July 1, indicates a positive reaction to the phase IIa results.
Advertisement